- Conditions
- Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
- Interventions
- Durvalumab / Tremelimumab Combination Therapy
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 33,591
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Povorcitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more
- Conditions
- Palmoplantar Keratoderma
- Interventions
- Tapinarof
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- COPD
- Interventions
- Glycopyrronium and Formoterol Fumarate (GFF) Dose 1, Glycopyrronium and Formoterol Fumarate (GFF) Dose 2, Glycopyrronium (GP) Dose 1, Glycopyrronium (GP) Dose 2
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Arimoclomol
- Drug
- Lead sponsor
- ZevraDenmark
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Orange, California • Miami, Florida + 4 more
- Conditions
- Radiculopathy, Sciatica
- Interventions
- VVZ-149, Lidocaine, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 13
- States / cities
- Brentwood, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
- Conditions
- Healthy
- Interventions
- LXR-623
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 19 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- EGFR Mutant Advanced Non-small Cell Lung Cancer
- Interventions
- JIN-A02
- Drug
- Lead sponsor
- J Ints Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Invasive Aspergillosis
- Interventions
- Posaconazole IV, Posaconazole PFS, Posaconazole tablet
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Orange, California • San Diego, California • Chicago, Illinois + 1 more
- Conditions
- Bipolar I Disorder, Schizophrenia
- Interventions
- OLZ/SAM
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Stanford, California + 12 more
- Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
- Interventions
- Otamixaban (XRP0673), Unfractionated Heparin, Percutaneous Coronary Intervention
- Drug · Procedure
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 947 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 37
- States / cities
- Los Angeles, California • Santa Ana, California • Washington D.C., District of Columbia + 31 more
- Conditions
- Alzheimer's Disease
- Interventions
- Remternetug (IV), Remternetug (SC), Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Canoga Park, California • Carlsbad, California + 66 more
- Conditions
- Contact Lens Care
- Interventions
- OptiFree Multi-Purpose Disinfecting Solution
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- Not listed
- Enrollment
- 233 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Portland, Maine
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
- Conditions
- Influenza
- Interventions
- Nitazoxanide, Oseltamivir, Placebo Oral Tablet, Placebo Oral Capsule
- Drug
- Lead sponsor
- Romark Laboratories L.C.
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 1,941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 136
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Hoover, Alabama + 121 more
- Conditions
- Alzheimer's Disease
- Interventions
- BIIB037, Placebo
- Drug · Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Delray Beach, Florida • Orlando, Florida • Beachwood, Ohio
- Conditions
- Healthy Participants
- Interventions
- JZP047, Placebo
- Drug · Other
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes
- Interventions
- ONO-7475 3mg once daily, ONO-7475 6mg once daily, ONO-7475 10mg once daily, ONO-7475 6mg + Venetoclax (70-400mg)
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 16
- States / cities
- Los Angeles, California • North Haven, Connecticut • Gainesville, Florida + 12 more
- Conditions
- Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
- Interventions
- Pregabalin, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Stanford, California • Chicago, Illinois + 6 more
- Conditions
- Safety Study
- Interventions
- IVMED-85 ophthalmic solution, Vehicle Ophthalmic Solution
- Drug
- Lead sponsor
- iVeena Delivery Systems, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- HIV Infections
- Interventions
- PGDM1400LS (5mg/kg, IV), PGDM1400LS (20mg/kg, IV), PGDM1400LS (20mg/kg, SC), PGDM1400LS (40mg/kg, IV), PGDM1400LS (40mg/kg, SC), PGDM1400LS (1.4g, IV), PGDM1400LS (1.4g, SC), VRC07-523LS (20mg/kg, IV), VRC07-523LS (20mg/kg, SC), VRC07-523LS (1.4g, IV), VRC07-523LS (1.4g, SC), VRC07-523LS (40mg/kg, IV), PGT121.414.LS (20mg/kg, IV), PGT121.414.LS (20mg/kg, SC), PGT121.414.LS (1.4g, IV), PGT121.414.LS (1.4g, SC), PGT121.414.LS (40mg/kg, IV)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
- Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Interventions
- Nilotinib (AMN107), imatinib (STI571)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Duarte, California + 22 more
- Conditions
- Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
- Interventions
- DPX-E7 vaccine, Cyclophosphamide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts